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INTRODUCTION 
 
Impulsive compulsive behaviours (ICBs) such as dopamine dysregulation syndrome, 
pathological gambling, compulsive sexual behaviour, punding, compulsive shopping and 
binge eating are recognised complications of dopaminergic treatment that affect at least 1 
in 7 patients with Parkinson’s disease (PD).1 Only a few studies provide long-term data on 
ICBs although any firm conclusions are limited by restricted follow up periods. We present 
long-term longitudinal data on 46 PD patients with ICBs with follow up for a mean period of 
8.2 years.  
 
METHODS 
 
Patients with PD and ICBs who participated in previous research studies from 2007 to 2012 
(V1) were invited for re-assessment (V2). Participants underwent a clinical interview and 
assessment with questionnaires and scales (detailed in supplementary materials). The 
diagnosis of ICBs was based on screening questionnaires and confirmed with a structured 
interview. The study received ethics approval. Data was analysed in SPSS 22. All variables 
were tested for normality and statistical tests chosen accordingly. A p value < 0.05 was 
considered significant. Bonferroni correction was applied for comparison between visits and 
significance was considered to have been reached when p < 0.025. 
 
RESULTS 
 
Of the 90 original participants, 46 were included. 8 declined to participate, 5 were lost to 
follow up and 31 had died (see supplementary figure 1). No cases of suicide or traumatic 
fatality were reported. Participants were followed up for 8.2 years (± 2.6). Three patients 
had a bi-allelic PARKIN mutation. See table 1 for demographic and clinical details at each 
visit and supplementary table 1 for results of the scales/questionnaires used at V2. 
 
Initial treatment of ICBs consisted of cessation of oral/transcutaneous dopamine agonists 
(DA) in 29 patients, reduction of DA dose in 13 and reduction of levodopa in 4. Seven 
patients (16.6%) developed dopamine agonist withdrawal syndrome (DAWS). Of the 46 
patients, 19 (41.3%) improved completely and were asymptomatic at V2, 26 (56.5%) 
improved partially and 1 (2.2%) had no change of the addictive behaviour. No patients 
experienced worsening of ICBs over time. Five patients re-started DA. Details on the 
outcome of ICBs according to treatment can be seen in supplementary figure 1. 
 
Participants were divided into two groups based on the presence of ICBs at V2 and 
compared to identify any factors associated with long-term remission (see supplementary 
table 2). Patients with active ICBs at V2 scored higher in the QUIP-RS, HADS total, HADS 
depression, UPDRS part I and Hoehn & Yahr scale. To assess if different ICBs were associated 
with different dopaminergic drugs, patients with DDS and/or punding (which are more 
associated with l-dopa use) were compared to patients with other ICBs such as pathological 
gambling (which are more associated with DA use). No differences were found (see 
supplementary tables 3-5).  
 
 
Table 1 - Comparison between visits 
 Visit 1 (V1) Visit 2 (V2) p value 
Age (years) 54.76 (± 9.7; 34 - 72) 61.7 (±10.2; 37 – 81)  <0.001* 
ICBs 46 (100%) 27 (58.7%) <0.001 
Multiple ICBs 27 (58.7%) N = 46 16 (59.2%) N = 27 0.754 
Types of ICBs DDS = 6 
CSB = 23  
PG = 13 
CS = 17 
CE = 11 
Punding = 23  
DDS = 3 
CSB = 13  
PG = 5 
CS = 5 
CE = 14 
Punding = 18 
0.508 
0.052 
0.008 
0.008 
0.629  
0.359 
UPDRS III 16.22 (± 7.87; 4 - 37)  34.65 (± 11.01; 12 - 61)  <0.001* 
Dyskinesias 29 (63%) 38 (82.6%) 0.022 
Cognitive 
impairment 
2 (4.3%) 15 (32.6%) 0.001 
Depression 14 (30.4%) 11 (23.9%) 0.629 
Anxiety 8 (17.4%) 15 (32.6%) 0.118 
Hallucinations 10 (21.7%) 12 (26.1%) 0.754 
Use of levodopa 41 (89.1%) 44 (95.6%) 0.375 
Use of DA 42 (91.3%) 18 (39.1%) <0.001 
DA type Pramipexole = 27 
Ropinirole = 12 
Rotigotine = 1 
Bromocriptine = 1 
Cabergoline = 1 
Pramipexole = 8 
Ropinirole = 3 
Rotigotine = 7 
 
Use of MAOi 8 (17.4%) 28 (60.9%) <0.001 
Use of 
Amantadine 
16 (34.8%) 37 (80.4%) <0.001 
Levodopa dose 713.75 (± 487.33; 150 – 2400) 
N = 41 
1021.91 (± 437.5; 200 – 
2222) N = 44 
0.001 
DA LEDD 255.6 (± 113; 52 – 600) N = 42 153.44 (± 86.9; 40 – 360) 
N = 18 
0.003 
Total LEDD 979.65 (±542.8; 300 – 2710) 1296.60 (± 457.7; 257 – 
2528) 
<0.001 
Infusion 
therapies 
Apomorphine – 1 (2.1%) Apomorphine: 6.5% (N=3) 
Duodopa: 2.17% (N=1) 
 
DBS 0 11 (23.9%) 
STN = 10; GPi = 1 
 
Differences between visits. ICBs – impulsive compulsive behaviours; DDS – dopamine dysregulation 
syndrome; CSB – compulsive sexual behaviour; PG – pathological gambling; CS – compulsive shopping; CE – 
compulsive eating; UPDRS – Unified Parkinson’s Disease; DA – oral or transcutaneous dopamine agonists; 
MAOi – monoamine oxidase inhibitors; LEDD – levodopa equivalent daily dose as described by Tomlinson et 
al, 2010; DBS – deep brain stimulation; STN – subthalamic nucleus; GPi – globus pallidus internus. Rating 
Scale. Results are expressed in total values with proportion, or mean values with standard deviation and 
range. Significant results after Bonferroni correction in bold. *paired t-test; Wilcoxon matched pairs;  
McNemar’s test.  
 
DISCUSSION 
 
Despite using different methodologies, all previous follow up studies have reported 
improvement of ICBs after cessation/reduction of DA.2-4 Reduction of dopaminergic 
medication also led to improvement in all but one of our patients. However, we found a 
lower remission rate (41.3%) than previously reported, despite achieving similar reduction 
in DA use to other reported studies. Continued use of DA as a consequence of DAWS, 
relapses of behavioural addictions following the necessary concomitant increase in l-dopa 
dosage, and the inclusion of more severe cases from a tertiary centre are possible 
explanations for the lower remission rate.  
 
Compared to V1, fewer patients were using DA and more were using MAOi and amantadine 
at V2. The increase in amantadine use is probably an attempt to control levodopa induced 
dyskinesias, a common comorbidity of ICBs.1 Although both these classes of drugs appear to 
be safer than DA in patients with ICBs, contradictory data has been published on the 
propensity of amantadine to induce ICBs and a few case reports of ICBs in patients receiving 
MAOi have also  been published.1 More patients were also taking rotigotine and 
apomorphine at V2. Some studies have reported a lower proclivity of both these drugs to 
induce ICBs.1  
 
The proportion of patients having multiple ICBs remained stable at V2, in agreement with a 
prospective two year study.5 However, we have found a higher prevalence of multiple ICBs 
than previously reported.1 The presence of ICBs was associated with depression and lower 
quality of life.1 ICBs at V2 were also associated with higher UPDRS part I scores, and more 
advanced disease. The latter finding is in contradiction to published data showing that ICBs 
are not associated with disease severity.5  Patients with more advanced disease require 
higher doses of dopaminergic treatment and may, therefore, be at increased risk of 
recurrence of ICBs. A third of patients exhibited cognitive impairment at V2, supporting 
previous work suggesting ICBs are not a risk factor for PD dementia.5  
 
A lower proportion of patients were using neuroleptic drugs at V2 compared with the 
findings of  Sohtaoglu and colleagues.3 In their study, neuroleptics were used routinely if 
patients did not improve after initial treatment with reduction of DA. DBS appears to be 
associated with low risk of ICBs, probably as a consequence of the reduction in 
dopaminergic treatment that usually follows the procedure. In our study, seven patients 
were still symptomatic after DBS, but none experienced worsening of ICBs.  
 
Potential limitations of this study are that only half of the patients were available for re-
assessment and there was no control group. The mortality rate found here is similar to what 
has been described among PD patients with similar age at disease onset. Diagnostic 
accuracy can also be a problem as patients and relatives commonly under-report ICBs.1 We 
believe the use of interviews aided by questionnaires at both visits contributed to accurate 
detections of ICBs. 
 
CONCLUSION 
 
In the longest follow up study of ICBs in PD to date, we have found a lower rate of remission 
of ICBs than reported in previous studies with shorter follow up periods. The most used 
treatment strategy was cessation of DA, but 40% of the patients were still receiving these 
drugs at follow up. Even when reduction or discontinuation of DA was possible it did not 
guarantee long-term remission. 
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